[ad_1]
Dakar, December 20
A parliamentary committee in Gambia mentioned on Tuesday that India-based drug maker Maiden Pharmaceuticals Ltd was accountable for the deaths of no less than 70 youngsters from acute kidney damage and referred to as on the federal government to pursue authorized motion.
Maiden’s managing director, Naresh Kumar Goyal, didn’t instantly reply to calls and messages from Reuters on Tuesday.
Chairperson of The Committee on Health, Hon. Amadou Camara lays report on its investigations into the deaths of no less than 66 youngsters from Acute Kidney Injury (AKI)#GambiaNationalAssembly pic.twitter.com/psTxoY83Mz
— National Assembly Watch-The Gambia (@knowyourNA) December 20, 2022
The World Health Organisation in October mentioned 4 medicinal syrups made by Maiden and imported by an area wholesaler had been probably linked to the deaths, which have shocked the West African nation since July. The medication had been pulled from the cabinets and Maiden’s manufacturing licence in India was suspended.
After its investigation, Gambia’s choose committee on well being reached an identical conclusion.
“All the cases of AKI are linked to the consumption of contaminated medical products…manufactured by Maiden Pharmaceuticals,” the committee’s chairperson Amadou Camara mentioned in an announcement to parliament.
Goyal on Friday informed Reuters that his firm had accomplished no unsuitable.
The WHO in October mentioned that lab evaluation confirmed “unacceptable” quantities of diethylene glycol and ethylene glycol within the medicines made by Maiden, which might be poisonous and result in acute kidney damage.
Earlier this month India informed the WHO that assessments of samples from the identical batches of syrups that had been despatched to Gambia had been compliant with authorities specs.
[ad_2]